KRA-533

Research use only, not for human use.

KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells.

KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells.

Western Blot Analysis Cell Line:HCC827 cells Concentration:10 μM Incubation Time:48 hours Result:Enhanced KRAS activity to a greater extent. Apoptosis Analysis Cell Line:H157 cells Concentration: 0~15 μM Incubation Time:48 hours Result:Enhanced KRAS activity in a dose-dependent manner, which was associated increased levels of pERK, ratio of active caspase 3/procaspase 3 and PARP cleavage, leading to apoptotic cell death.

Animal Model:Nu/Nu nude mice (mutant KRAS xenografts) Dosage:0~30 mg/kg Administration:i.p.; 28 days Result:Suppressed tumor growth in a dose-dependent manner in lung cancer mutant KRAS xenografts and induced apoptosis and autophagy in tumor tissues in a dose-dependent manner.

———

Others

Other Targets

KRAS

———

———

10161-87-2

314.179

C13H16BrNO3

>98% (HPLC)

DMSO : 250 mg/mL (795.72 mM; ultraphonic; )

———

——

(-20℃)

With Ice Pack

≥ 2 years